Eli Lilly and Company is currently researching a dual agonist called tirzepatide, which has outperformed semaglutide in phase 3 clinical trials
Common side effects may include: Early fullness (feeling satisfied sooner while eating) Bloating or mild stomach discomfort Heartburn or indigestion Constipation or, less commonly, loose stools If symptoms occur, they often improve by eating smaller meals, slowing your pace while eating, drinking plenty of water, and limiting greasy or high-fat foods
ACC/AHA In 2019, the ACC and AHA published Guidelines on Primary Prevention of Cardiovascular Disease, suggesting that GLP-1 RA may help reduce CVD risk in patients with T2DM who require glucose-lowering medications despite lifestyle changes and use of metformin (Class 2a, Level of Evidence (LoE) B-R) [42]
3,4 This is why GLP-1 RAs were initially studied exclusively for diabetes management
It helps regulate blood sugar, slows digestion, increases feelings of fullness, and signals the brain to reduce appetite
In other words, your mileage may vary
